CellPoint B.V.
https://cellpoint.bio/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CellPoint B.V.
Galapagos Keeps Analysts Guessing About Future Plans
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Galapagos Enters Cancer Field With CellPoint Buy
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy